RecruitingPhase 1NCT04243785
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Studying Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Edgewood Oncology Inc.
- Principal Investigator
- Zung Thai, MDEdgewood Oncology Inc.
- Intervention
- BTX-A51(drug)
- Enrollment
- 80 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Study locations (3)
- City of Hope National Medical Center, Duarte, California, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04243785 on ClinicalTrials.govOther trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07384715First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)Genmab
- RECRUITINGPHASE1NCT06670222Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)Groupe Francophone des Myelodysplasies
- RECRUITINGPHASE1NCT06552416Safety of MT-401-OTS in Patients With Relapsed AML or MDSMarker Therapeutics, Inc.
- RECRUITINGNANCT07121140Home Blood TransfusionsThomas Jefferson University
- RECRUITINGNANCT05924074Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)University Hospital, Bordeaux
- RECRUITINGNCT06379945Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA)Instituto de Investigación Biomédica de Salamanca
- RECRUITINGPHASE1, PHASE2NCT05181735Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESAGroupe Francophone des Myelodysplasies
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04798339Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESAH. Lee Moffitt Cancer Center and Research Institute